DR. LAURA ELLEN PURDY MD NPI 1093058463

NPI Details

DR. Laura Ellen Purdy, MD is a family medicine in Calabasas, CA. The provider is family Medicine is the medical specialty which is concerned with the total health care of the individual and the family. It is the specialty in breadth which integrates the biological, clinical, and behavioral sciences. The scope of family medicine is not limited by age, sex, organ system, or disease entity. DR. Laura Ellen Purdy, MD NPI is 1093058463. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a female.

The provider's business location address is:

23693B CALABASAS RD STE 100
CALABASAS, CA
ZIP 91302-502
Phone: (818) 493-7588

The NPI 1093058463 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days (HCPCS:99454)
• Management using the results of remote vital sign monitoring per calendar month, first 20 minutes (HCPCS:99457)
• Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment (HCPCS:99453)
• Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count (HCPCS:K1034)
• Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes (HCPCS:99458)
• Adm sarscov2 50mcg/0.25mlbst (HCPCS:0064A)
• Established patient office or other outpatient visit, 10-19 minutes (HCPCS:99212)
• Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus (HCPCS:87426)
• Severe acute respiratory syndrome coronavirus 2 (covid-19) vaccine, mrna-lnp, spike protein, preservative free, 100 mcg/0.5ml dosage, for intramuscular use (HCPCS:91301)
• Sarscov2 vac 50mcg/0.25ml im (HCPCS:91306)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen (HCPCS:87635)
• Established patient home visit, typically 15 minutes (HCPCS:99347)
• Adm sarscov2 30mcg/0.3ml bst (HCPCS:0004A)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Severe acute respiratory syndrome coronavirus 2 (covid-19) vaccine, mrna-lnp, spike protein, preservative free, 30 mcg/0.3ml dosage, diluent reconstituted, for intramuscular use (HCPCS:91300)
• Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional (HCPCS:99211)
• Detection test by immunoassay with direct visual observation for severe acute respiratory syndrome coronavirus 2 (covid-19) (HCPCS:87811)
• Administration of influenza virus vaccine (HCPCS:G0008)
• Influenza vaccine split virus, preservative free (HCPCS:90662)
• Adm sarscov2 100mcg/0.5ml3rd (HCPCS:0013A)
• Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus and influenza (HCPCS:87428)
• Adm sarscov2 30mcg/0.3ml 3rd (HCPCS:0003A)
• Adm sarscov2 50 mcg/.5 mlbst (HCPCS:0094A)
• Respiratory infectious agent detection by rna for severe acute respiratory syndrome coronavirus 2 (covid 19), influenza a, influenza b, and respiratory syncytial virus, upper respiratory specimen, each reported as detected or not detected (HCPCS:0241U)
• Sarscov2 vac 50mcg/0.5ml im (HCPCS:91309)
• Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment (HCPCS:99453)
• Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days (HCPCS:99454)
• Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage (HCPCS:90686)
• Management using the results of remote vital sign monitoring per calendar month, first 20 minutes (HCPCS:99457)
• Fee covid-19 vac 13 res (HCPCS:0124A)
• Severe acute respiratory syndrome coronavirus 2 (covid-19) vaccine, dna, spike protein, adenovirus type 26 (ad26) vector, preservative free, 5x1010 viral particles/0.5ml dosage, for intramuscular use (HCPCS:91303)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Adm sarscov2 vac ad26 .5ml b (HCPCS:0034A)
• Administration of pneumococcal vaccine (HCPCS:G0009)
• Detection test by immunoassay with direct visual observation for influenza virus (HCPCS:87804)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (covid-19) vaccine, mrna-lnp, spike protein, preservative free, 100 mcg/0.5ml dosage; second dose (HCPCS:0012A)
• Established patient home visit, typically 40 minutes (HCPCS:99349)
• Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (covid-19) vaccine, mrna-lnp, spike protein, preservative free, 30 mcg/0.3ml dosage, diluent reconstituted; second dose (HCPCS:0002A)
• Pneumococcal vaccine, 23-valent (HCPCS:90732)
• Pneumococcal vaccine, 13-valent (HCPCS:90670)

The enumeration date for this NPI number is 4/3/2013 and was last updated on 3/25/2024.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: